Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06022757
Status:
RECRUITING
Last Update Posted:
2024-02-23
First Post:
2023-08-17
Brief Title:
Study of XNW5004 Tablet in Combination With KEYTRUDA Pembrolizumab in Subjects With Advanced Solid Tumors Who Failed Standard Treatments KEYNOTE F19
Sponsor:
Evopoint Biosciences Inc
Organization:
Evopoint Biosciences Inc
Study Overview
Official Title:
A Phase IbII Study of XNW5004 Tablet in Combination With KEYTRUDA Pembrolizumab in Subjects With Advanced Solid Tumors Who Failed Standard Treatments KEYNOTE F19
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA pembrolizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| KEYNOTE F19 | OTHER | None | None |
| MK-3475-F19 | OTHER | Merck Sharp Dohme LLC | None |